Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map

Immune Response BioPharma, Inc. TM


Drug Discovery Pipeline: © 2010-2018

undefined

 

 

  

                                                                                                                                       

Patent Coverage through 2027 with The King Patent U.S. Patent 8,053,197 Ownership Issued to Immune Response BioPharma, Inc. for the Treatment & Vaccination of Auto-Immune Diseases Proprietary FOXP3+ Expression Technology.

IRBP Featured Vaccines in PhRMA 2013 Biologics Report 

NeuroVax TM : IR902 The Company's Flagship Vaccine for Multiple Sclerosis 


NeuroVax has been Granted both FDA Pediatric Orphan Designation & FDA Fast Track Designation for SPMS



NeuroVax is a First in Class MS Vaccine Treatment    NeuroVax Video

undefined                                                              



REMUNE TM: HIV-1 Immunogen FDA BLA Filing 

REMUNE is a First in Class & Best in Class HIV/AIDS VACCINE has been Granted FDA Pediatric Orphan Designation & is a Rescue Treatment for Patients with HIV/AIDS a First Line Therapeutic HIV/AIDS Vaccine Safe & Effective against Multi-Drug Resistance & Drug Naive Patients a Life Saving HIV/AIDS Vaccine with Dosing 100ug every 3 months. 

undefined


Remune TM Pediatric HIV Vaccine Indication: 

 March 31st 2017 FDA BLA Filing 

FDA Orphan Pediatric Designation 


RemuneX TM:  IR-103 Phase 3 Clinical Trials Planning Stage Remune + Amplivax 

                            Next Generation HIV/AIDS VACCINE


 

Zorcell TM:  IR-502 Psoriasis Vaccine Phase IIb Clinical Trials 


 


RAVAX TM:  IR-501 Rheumatoid Arthritis Vaccine Phase 3 Clinical Trials 


  

CrohnsVax TM:  IR-777 Crohn's Disease Vaccine Phase 1 Clinical Trial

 

 

GoutVax TM:  IR-888 Gout Vaccine IL-1 Candidate Immunereszumab TM

                      Pre-Clinical Studies 

 

DiabetesVax TM:  IR-1000 Diabetes Vaccine IL-1 Candidate Immunereszumab TM

                                    Pre-Clinical Studies

  

HeartVax TM:  IR-1002 Cardiology Anti-Cholesterol Drug IL-1 Candidate Immunereszumab TM

                                   Pre-Clinical Studies

 

MelanoVax TM:  IR-222 Melanoma Vaccine Candidate Pre-Clinical Studies



DermaVax  TM:  IR-444  Psoriasis & Eczema Vaccine Candidate Pre-Clinical Studies



Sepsicillin TM:  IR-999  BPI Antibiotic Formulation First in Class Sepsis Drug



NeurOral TM:  IR-007  Next Generation Multiple Sclerosis Oral Drug Pre-Clinical Studies


RemuneVax TM:  IR-2020 Annual Preventative HIV/AIDS Vaccine Pre-Clinical Studies

                                based on the Current Year Mutated HIV Stain 


EbolaVaxx TM:  IR-E101  Ebola Virus Vaccine VP40 Depleted Whole Killed Vaccine in IFA (VP24 Antigen in IFA)

 

Immune Response BioPharma, Inc. TM  

Copyright © 2010-2018        All Rights Reserved        www.immuneresponse.net